Hims & Hers slips ahead of White House meeting on peptide policy
HIMS•Hims & Hers Health shares fell 4.5% ahead of a White House meeting on peptide compounding policies. The meeting, requested by the company, is scheduled for 2 p.m. ET on Oct. 23.
1. Policy review meeting
A White House review meeting on peptide compounding policies is scheduled for 2 p.m. ET on Oct. 23, after Hims & Hers Health requested it. Last week, the FDA submitted a proposed policy change for White House review that could make it easier for pharmacies to compound certain peptides.
2. Company plans
Hims & Hers has said it plans to offer peptides if regulations permit. Health Secretary Robert F. Kennedy Jr. said earlier this week that the administration aims to expand access to peptides by creating a regulated marketplace.
